|
gptkbp:instanceOf
|
gptkb:drug
|
|
gptkbp:approvedBy
|
gptkb:FDA
2017
|
|
gptkbp:ATCCode
|
gptkb:A06AH05
|
|
gptkbp:bioavailability
|
~20%
|
|
gptkbp:brand
|
gptkb:Symproic
|
|
gptkbp:CASNumber
|
gptkb:864821-90-9
|
|
gptkbp:contraindication
|
patients with known or suspected gastrointestinal obstruction
|
|
gptkbp:eliminationHalfLife
|
11 hours
|
|
gptkbp:excretion
|
urine
feces
|
|
gptkbp:hasInChIKey
|
gptkb:QJQYQKZDHGQXQJ-UHFFFAOYSA-N
|
|
gptkbp:hasMolecularFormula
|
C32H34N4O6
|
|
gptkbp:hasSMILES
|
CC1=CC(=O)N(C2=CC=CC=C12)C3CCN(CC3)CC4=CC=C(C=C4)C(=O)N5CCN(CC5)C(=O)COC6=CC=CC=C6
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
DB11363
|
|
gptkbp:indication
|
treatment of opioid-induced constipation in adults with chronic non-cancer pain
|
|
gptkbp:marketedAs
|
gptkb:Shionogi_Inc.
|
|
gptkbp:mechanismOfAction
|
peripherally-acting mu-opioid receptor antagonist
|
|
gptkbp:metabolism
|
liver (CYP3A4)
|
|
gptkbp:molecularWeight
|
570.6 g/mol
|
|
gptkbp:name
|
gptkb:Naldemedine
|
|
gptkbp:pregnancyCategory
|
Not assigned (US FDA)
|
|
gptkbp:proteinBinding
|
~93%
|
|
gptkbp:PubChem_CID
|
gptkb:DB11363
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
nausea
vomiting
diarrhea
abdominal pain
|
|
gptkbp:status
|
true
|
|
gptkbp:bfsParent
|
gptkb:alectinib
|
|
gptkbp:bfsLayer
|
6
|